All News

The novel therapy combines aztreonam, a monobactam antibiotic, and avibactam, a β-lactamase inhibitor.

The investigational molecule with “JAK-inhibitor-like efficacy and IL4/IL13-like safety,” was cleared in Q4 2024 by the FDA for an IND application, the company said.

The study will assess the safety and efficacy of a next-generation COVID-19 vaccine via nasal spray and inhalation.

The FDA has set the Prescription Drug User Fee Act target action date for bronchiectasis for August 12, 2025, Insmed Incorporated announced.

Your daily dose of the clinical news you may have missed.

William Grady, MD, coauthor of the ECLIPSE trial, discusses how the Shield cfDNA blood-based test compares to traditional CRC screening methods.

In letters to the FDA and Fox Broadcasting, PSM enumerated the laws abrogated and the potential harms of the ad being viewed by 200 million people on February 9, 2025.

Onapgo is the first and only subcutaneous apomorphine infusion device for the treatment of motor fluctuations in people with advanced Parkinson disease.

Opioid prescribing has seen its extremes, from the 5th Vital Sign era in the aughts to the CDC restrictions of 2016. Mariano talks about the environment right now.

Hardware or software changes as well as user adjustments may disable or mute alerts for elevated glycemia, medication use, and other diabetes management essentials, the agency said.